{"id":798332,"date":"2025-01-07T07:28:06","date_gmt":"2025-01-07T12:28:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/"},"modified":"2025-01-07T07:28:06","modified_gmt":"2025-01-07T12:28:06","slug":"scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/","title":{"rendered":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results"},"content":{"rendered":"
\n

TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (\u201cMitoCareX\u201d), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results.<\/p>\n

MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX\u2019s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments.<\/p>\n

By leveraging its in-vitro screening systems related to mitochondria, MitoCareX corroborated the anti-cancer biological activity of several small molecule structures discovered out of millions of them that were virtually screened the addition of pancreatic cancer to its existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions.<\/p>\n

Additionally, MitoCareX continues its efforts to create a predictive artificial intelligence (AI) model, utilizing the extensive virtual data generated during its discovery processes. This model is designed to efficiently navigate broader chemical spaces, with the goal of uncovering more novel anti-cancer scaffolds targeting the SLC25 protein family.<\/p>\n

Pancreatic cancer remains one of the most aggressive and difficult-to-treat cancers, with a significant unmet medical need. According to the American Cancer Society<\/a>, the 5-year survival rate for pancreatic cancer is just 12% (as of 2023), one of the lowest among all cancers. It is the third leading cause of cancer-related deaths in the United States.<\/p>\n

\n About\u00a0SciSparc\u00a0Ltd. (Nasdaq: SPRC):<\/strong>\n <\/p>\n

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc\u2019s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and\/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds\u2019 oil-based products on the\u00a0Amazon.com<\/u><\/a>\u00a0Marketplace.<\/p>\n

\n Forward-Looking Statements:<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses MitoCareX\u2019s encouraging initial in-vitro results, that the addition of pancreatic cancer to MitoCareX\u2019s existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions, potential benefits and advantages of MitoCareX\u2019s predictive AI model and significant unmet need for pancreatic cancer. Because such statements deal with future events and are based on SciSparc\u2019s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on\u00a0April 1, 2024, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.<\/p>\n

Investor Contact:
IR@scisparc.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (\u201cMitoCareX\u201d), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results. MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX\u2019s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments. By … <\/p>\n

Continue reading “SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798332","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (\u201cMitoCareX\u201d), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results. MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX\u2019s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments. By … Continue reading "SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T12:28:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results\",\"datePublished\":\"2025-01-07T12:28:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/\"},\"wordCount\":622,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/\",\"name\":\"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==\",\"datePublished\":\"2025-01-07T12:28:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/","og_locale":"en_US","og_type":"article","og_title":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - Market Newsdesk","og_description":"TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (\u201cMitoCareX\u201d), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results. MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX\u2019s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments. By … Continue reading \"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T12:28:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results","datePublished":"2025-01-07T12:28:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/"},"wordCount":622,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/","name":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==","datePublished":"2025-01-07T12:28:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzc2MSM2NjgyMjM2IzUwMDEwMjUyNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scisparc-mitocarex-bio-expands-research-to-pancreatic-cancer-following-initial-in-vitro-positive-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798332"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798332\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}